OMB approves the
package for one year. Prior to re-submission for approval, FDA will
solicit comment on, evaluate, and report on the accuracy of their
burden estimates. Furthermore, if FDA receives any comments on this
submission, they are to immediately forward them to OMB.
Inventory as of this Action
Requested
Previously Approved
09/30/1996
09/30/1996
1
0
0
24
0
0
0
0
0
The existing rule provides conditions
for the marketing of antheimintic drug products for OTC use. One
provision of the regulation requires the preparation and
distribution of a consumer package insert related to the use of the
drug by discussing pinworm infestation and its symptoms,
identification, detection, and treatment.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.